One promising approach for the enhancement of innate cell engager efficacy targeting EGFR is to combine these agents with allogeneic or autologous NK cell products in order to increase the proportion of effector cell/tumor cell pairings following the trafficking and homing of both therapeutic modalities to tumor tissue. The gene discussed is EGFR; the disease is neoplasm.